About
Forest Hills Lab
Incorporated in 2017, Forest Hills Lab (FHL) is an innovative global life sciences
company that targets restoration through regenerative technology.
All three core operating divisions of FHL share the common mission to
improve well-being in an aging society.
FHL Therapeutics Story
The therapeutic division of Forest Hills Lab is a clinical stage
biopharmaceutical platform with seven potentially disease-modifying
therapies for neurological conditions. Our compounds demonstrated
promising outcomes in addressing various neurodegenerative disease pathways.
Our two lead compounds are FHL-101, which recently completed a
Phase 1 clinical trial, and FHL-301, which is preparing to enter a
Phase 2 clinical trial in Parkinson’s.
Our platform seeks partnerships to add to pipeline candidates to be
developed to a clinical stage and collaborate on co-development and
licensing-out arrangements.
medical injectable aesthetics and AI Robotics.
- Develop and manufacture globally marketed comprehensive medical- and cosmetic-grade aesthetic solutions
- Positioned to benefit from rigorous scientific breakthroughs, market changes, and regulatory dynamics
- High-value partnerships together with AI integration in sales and marketing to expand global market access
- New FHL division formed by joint foces of renowned humanoid robot developer, Hanson Robotics, and decentralized AI platform, SingulartyNet
- Leveraging expertise in creating Sophia, the world-famous AI robot, AHL introduces Grace, the healthcare sector-focused AI avatar and medical robot
- Pioneer in developing an AI-powered B2B2C platform to empower the management of healthcare vertical segment
Mstone Healthcare Partners
Forest Hills Lab’s Controlling Shareholder
Mstone Healthcare Partners is an incubator of biotech, healthcare and AI companies developing and growing portfolio companies by building upon novel technology as well as human and investment capital.